Affogata, which helps brands manage their online reputation, raises $5.5M
22 Apr, 2021
– Boston Immune Technologies and Therapeutics, Inc. (BITT) is a Boston, MA based developer of novel TNF Superfamily antagonist antibodies.
– Company raised $10M Series A/A1 financing.
– Investors included BeiGene, Ltd., along with undisclosed private investors and prior investors Hatteras Venture Partners and EGP Investments.
– The company intends to use the funds for the clinical development of BIR2101, a novel, TNFR2 antagonist antibody for indications in oncology and infectious disease and additional pipeline candidates.